Stockwinners Market Radar for December 01, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

13:09 EDT ImmunoGen presents new data highlighting potential of novel ADCs at ASH - ImmunoGen announced that new data from the ongoing Phase 1 studies of IMGN632 and IMGN779, next-generation CD123- and CD33-targeting ADCs, respectively, in patients with relapsed or refractory adult acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm will be presented during an oral session at the 60th American Society of Hematology Annual Meeting in San Diego. Preclinical data for IMGN632 as a monotherapy in BPDCN patient-derived xenografts, as well as in combination with a PARP inhibitor in AML models, will also be presented at the conference. The data presented at ASH demonstrate the potential of ADCs generated from the company's IGN platform to overcome the narrow therapeutic window seen with previous generations of DNA-targeted agents and offer new treatment options for AML and other hematological malignancies. Key initial findings from the Phase 1 study of IMGN632 include: IMGN632 was administered to 33 patients over dose levels ranging from 0.015 to 0.45 mg/kg intravenously every three weeks; IMGN632 displays a tolerable safety profile and anti-leukemia activity at doses up to 0.3 mg/kg; Pharmacokinetic exposures and pharmacodynamic CD123 saturation increase with dose; Reported adverse events were consistent with underlying disease, with no evidence of cumulative toxicity following multiple doses; Single dose limiting toxicities were seen at the three highest dose levels tested: one prolonged neutropenia and two reversible cases of veno-occlusive disease; Six of 23 evaluable AML patients across multiple dose levels achieved an objective response, including two complete remissions and four CRs with incomplete recovery in heavily pretreated patients, including over 60% of patients with primary or relapsed refractory disease; Two of three evaluable BPDCN patients achieved an objective response after a single dose of IMGN632, 1 CRi and 1 partial remission; Enrollment in expansion cohorts continues to identify a recommended Phase 2 dose and schedule for both AML and BPDCN. Key findings presented from the Phase 1 study of IMGN779 include: IMGN779 continues to display a tolerable safety profile with repeat dosing across a wide range of doses explored in 57 patients with relapsed AML; Plasma IMGN779 concentrations indicate consistent and sustained exposure through seven days at doses greater than or equal to 0.39 mg/kg; the weekly schedule provides more consistent pharmacodynamic CD33 saturation; Reported AEs were consistent with underlying disease, and with no evidence of cumulative toxicity following multiple doses; One DLT of veno-occlusive disease was observed at the highest dose tested on the weekly schedule, 1.2 mg/kg; Anti-leukemia activity was seen at doses greater than or equal to 0.39 mg/kg in both schedules; Enrollment continues to identify the recommended Phase 2 dose and schedule.

13:03 EDT Tegna blacks out Dish customers in 39 Markets - Tegna (TGNA) blacked out Dish (DISH) customers' access to its 49 local channels in 39 markets across 34 states and the District of Columbia. Tegna is blocking consumers in an effort to gain negotiating leverage as it demands nearly double the monthly rates for its local channels, even as broadcast TV ratings decline. "Tegna refused Dish's offer to extend the contract, instead choosing to black out its stations on the eve of college football's conference championships and during the homestretch for the NFL season. It couldn't be more obvious that Tegna is using its own viewers as leverage as it demands nearly double the monthly rates, even as ratings on broadcast TV are down double digits," said Andy LeCuyer, Dish senior vice president of Programming. "The channels could come back today if Tegna would allow it, and we can restore the channels immediately if they give us the green light," added LeCuyer.